SCHEMBL2837601

SCHEMBL2837601

CON(C)C(=O)C(NC(=O)OC(C)(C)C)c1ccc(C)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 1/20 0.40
BTK Q06187 1/20 0.40
LMNA P02545 5/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
S1PR3 Q99500 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 6/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
HTT P42858 2/20 0.36
TRPA1 O75762 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRB2 P47870 1/20 0.35
POLB P06746 1/20 0.35
AAK1 Q2M2I8 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833348 0.88 S1PR3 (0.41) JAK3BTKS1PR3ALDH1A1CTSS
SCHEMBL2833275 0.87 PDE2A (0.40) JAK3BTKS1PR3CTSSCTSK
SCHEMBL2834847 0.86 S1PR3 (0.41) JAK3BTKKMT2AMEN1S1PR3
SCHEMBL15670019 0.84 JAK3 (0.43) JAK3BTKLMNAKMT2AMEN1
SCHEMBL2834101 0.84 S1PR3 (0.41) JAK3BTKKMT2AMEN1S1PR3
SCHEMBL2839359 0.83 S1PR3 (0.44) LMNAKMT2AMEN1S1PR3SMN1; SMN2
SCHEMBL2832308 0.81 S1PR3 (0.48) JAK3BTKLMNAS1PR3SMN1; SMN2
SCHEMBL2837436 0.80 JAK3 (0.42) JAK3BTKCTSSCTSK
SCHEMBL14847752 0.80 S1PR3 (0.45) JAK3BTKLMNAS1PR3ALDH1A1
SCHEMBL2834038 0.80 S1PR3 (0.45) JAK3BTKLMNAS1PR3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 JAK3 3843/4885BTK 1832/4885LMNA 4424/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 JAK3 3843/4885BTK 1832/4885LMNA 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.